Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High – Time to Buy?
by Sarita Garza · The Markets DailyDianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report)’s share price reached a new 52-week high on Friday . The stock traded as high as $114.60 and last traded at $114.7810, with a volume of 282797 shares. The stock had previously closed at $109.60.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on DNTH. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. HC Wainwright upped their price objective on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Wedbush increased their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $124.27.
Check Out Our Latest Report on DNTH
Dianthus Therapeutics Price Performance
The company has a market cap of $6.31 billion, a price-to-earnings ratio of -27.84 and a beta of 1.22. The firm has a 50-day moving average price of $96.76 and a 200 day moving average price of $82.61.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. On average, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, Director Simon Read sold 2,777 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $109.55, for a total transaction of $304,220.35. Following the transaction, the director directly owned 2,777 shares of the company’s stock, valued at approximately $304,220.35. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marino Garcia sold 166,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $108.11, for a total value of $17,946,260.00. Following the completion of the sale, the chief executive officer owned 65,292 shares of the company’s stock, valued at approximately $7,058,718.12. This trade represents a 71.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 284,306 shares of company stock worth $29,289,369. 3.02% of the stock is currently owned by insiders.
Institutional Trading of Dianthus Therapeutics
A number of institutional investors have recently modified their holdings of DNTH. BlackRock Inc. acquired a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth $401,990,000. Vestal Point Capital LP lifted its position in Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after purchasing an additional 1,499,931 shares during the period. Wellington Management Group LLP grew its stake in Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after buying an additional 2,503,311 shares in the last quarter. Vanguard Group Inc. grew its stake in Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after buying an additional 406,254 shares in the last quarter. Finally, TCG Crossover Management LLC increased its holdings in Dianthus Therapeutics by 11.7% in the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after buying an additional 175,000 shares during the period. 47.53% of the stock is currently owned by institutional investors.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.